Metastatic Non Small Cell Lung Cancer Clinical Trials

19 recruitingLast updated: June 17, 2026

There are 19 actively recruiting metastatic non small cell lung cancer clinical trials across 49 countries. Studies span Phase 3, Phase 1, Phase 2, Not Applicable. Top locations include New York, New York, United States, Barcelona, Spain, Los Angeles, California, United States. Updated daily from ClinicalTrials.gov.


Metastatic Non Small Cell Lung Cancer Trials at a Glance

19 actively recruiting trials for metastatic non small cell lung cancer are listed on ClinicalTrialsFinder across 6 cities in 49 countries. The largest study group is Phase 3 with 8 trials, with the heaviest enrollment activity in New York, Barcelona, and Los Angeles. Lead sponsors running metastatic non small cell lung cancer studies include Memorial Sloan Kettering Cancer Center, Centre Hospitalier Universitaire Dijon, and AstraZeneca.

Browse metastatic non small cell lung cancer trials by phase

Treatments under study

About Metastatic Non Small Cell Lung Cancer Clinical Trials

Looking for clinical trials for Metastatic Non Small Cell Lung Cancer? There are currently 19 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Metastatic Non Small Cell Lung Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Metastatic Non Small Cell Lung Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 119 of 19 trials

Recruiting
Phase 3

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

Non-small Cell Lung CancerAdvanced Non-Small Cell Lung CancerMetastatic Non Small Cell Lung Cancer+3 more
ArriVent BioPharma, Inc.480 enrolled74 locationsNCT07185997
Recruiting
Phase 2Phase 3

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Advanced Non-Small Cell Lung CancerMetastatic Non Small Cell Lung Cancer
Mirati Therapeutics Inc.626 enrolled770 locationsNCT04613596
Recruiting
Phase 3

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Lung CancerNon-small Cell Lung CancerCarcinoma, Non-Small Cell Lung+3 more
Pfizer1,410 enrolled346 locationsNCT07222566
Recruiting
Phase 1

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Locally Advanced Hepatocellular CarcinomaLocally Advanced MelanomaMetastatic Hepatocellular Carcinoma+7 more
National Cancer Institute (NCI)30 enrolled1 locationNCT06066138
Recruiting
Phase 2

Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

Metastatic Non Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center571 enrolled18 locationsNCT04410796
Recruiting
Phase 2

Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung CancerNSCLCAdvanced Non-Small Cell Lung Cancer+1 more
Virginia Commonwealth University40 enrolled2 locationsNCT06731413
Recruiting
Phase 3

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Metastatic Non Small Cell Lung Cancer
AstraZeneca744 enrolled303 locationsNCT06417814
Recruiting
Phase 3

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations

Metastatic Non Small Cell Lung Cancer
Daiichi Sankyo740 enrolled243 locationsNCT05215340
Recruiting
Phase 1

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

Non-small Cell Lung CancerMetastatic Lung CancerNSCLC+3 more
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)350 enrolled35 locationsNCT06343402
Recruiting
Phase 1Phase 2

Safety and Efficacy of OBX-115 in Advanced Solid Tumors

Lung CancerMelanomaNon-small Cell Lung Cancer+4 more
Obsidian Therapeutics, Inc.208 enrolled9 locationsNCT06060613
Recruiting
Phase 2

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

Metastatic Non Small Cell Lung Cancer
Iovance Biotherapeutics, Inc.170 enrolled91 locationsNCT04614103
Recruiting
Phase 3

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

Metastatic Non Small Cell Lung Cancer
NovoCure GmbH734 enrolled90 locationsNCT06216301
Recruiting
Phase 1

MOv19-BBz CAR T Cells in FRa+ Cancers

Recurrent Lung Non-Small Cell CarcinomaMetastatic Non Small Cell Lung Cancer
University of Pennsylvania10 enrolled1 locationNCT07116057
Recruiting
Phase 3

Standard Maintenance Therapy (SMT) vs Local Consolidative Radiation Therapy and SMT in OM-NSCLC

Oligometastatic DiseaseMetastatic Non Small Cell Lung Cancer
Tata Memorial Hospital190 enrolled1 locationNCT05278052
Recruiting
Phase 1

A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer

Lung CancerNon-small Cell Lung CancerMetastatic Non Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center5 enrolled7 locationsNCT06863233
Recruiting

Pilot Study of the Contribution of Fractional Exhaled Nitric Oxide as a Prognostic Marker of Response to Anti-PD-L1 Immunotherapy in Non-small Cell Lung Cancer

Metastatic Non Small Cell Lung Cancer
Centre Hospitalier Universitaire Dijon56 enrolled1 locationNCT05985330
Recruiting

Feasibility Study of Tissue and Blood Collection in Oncogene-addicted and Neoadjuvantly Treated Non Small Cell Lung Cancer

Non-small Cell Lung CancerMetastatic Non Small Cell Lung CancerOncogene-addicted Non Small Cell Lung Cancer+3 more
Royal Marsden NHS Foundation Trust100 enrolled1 locationNCT07008742
Recruiting
Phase 3

Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer

OligoProgressive Metastatic DiseaseNSCLC Stage IVMetastatic Non Small Cell Lung Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University104 enrolled1 locationNCT06523673
Recruiting
Not Applicable

The Impact of Probiotic on Survival and Treatment Response in Metastatic Non-small Cell Lung Cancer Patients

Metastatic Non Small Cell Lung Cancer
Necmettin Erbakan University100 enrolled1 locationNCT06428422